Refametinib (BAY86-9766), a novel potent allosteric MEK1/2 inhibitor from Bayer pharmaceuticals has undergone extensive preclinical testing in solid tumours including breast cancer [25, 34]. This evidence concerns the gene MAP2K1 and breast cancer.